Sumitomo Pharma Oncology (SMP Oncology) is committed to advancing translational research on novel pathways. Below is an exploration of our investigational products and the science that catalyzes their potential.
- Mechanism of action graphics are for illustrative purposes only
- Additional, ongoing clinical trials conducted in Japan by Sumitomo Pharma Co., Ltd., are not listed on this website. For information about these trials, please visit www.sumitomo-pharma.co.jp/rd/clinical/pipeline
- All development candidates are investigational agents, and their safety and efficacy have not been established. There is no guarantee that any of these agents will receive health authority approval or become commercially available in any country for the uses being investigated
- For additional information on clinical studies, including studies that are actively recruiting, please see www.clinicaltrials.gov or contact us
AML=acute myeloid leukemia; ALL=acute lymphocytic leukemia; AXL=member of the Tyro3-Axl-Mer (TAM) subfamily; CDK=cyclin-dependent kinase; EBP=emopamil-binding protein; LXR=liver x receptor; MCL-1=myeloid-cell leukemia 1; MLL=mixed-lineage leukemia; NK cells=natural killer cells; PIM=proviral integration site for Moloney murine leukemia virus; PK=pyruvate kinase; PKM2=pyruvate kinase M2 isoform; RTK=receptor tyrosine kinase; TLR=Toll-like receptor.
Our latest publications
SMP Oncology research and discovery teams are dedicated to finding the next breakthrough in oncology. See our latest publications and presentations to explore their work.Publications and presentations